Oxytocin vs Mazdutide
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Oxytocin is a 9-amino acid neuropeptide produced in the hypothalamus with diverse roles in social bonding, trust, stress reduction, and sexual function. Exogenous administration is used therapeutically to improve social cognition, reduce anxiety, and enhance intimacy.
- Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Innovent Biologics and Eli Lilly. Phase 2 trials in Chinese populations demonstrated up to 11.3% body weight reduction at 6 mg over 24 weeks. It also improves liver fat, glycemic control, and lipid profiles. Phase 3 trials are ongoing primarily in China.
- Half-Life
- ~3–5 minutes (IV); ~30–60 minutes (intranasal, CNS effects persist longer)
- ~7 days
- Admin Route
- Intranasal, SubQ, IV
- SubQ
- Research
- —
- —
- Typical Dose
- 20–40 IU
- 1.5 mg → 3 mg → 4.5 mg → 6 mg
- Frequency
- As needed (not daily long-term)
- Once weekly
- Key Benefits
- Enhances social bonding and trust
- Reduces social anxiety and fear of rejection
- Improves autism spectrum symptoms (social cognition)
- Reduces cortisol and stress reactivity
- Enhances sexual arousal and intimacy
- Promotes maternal behavior and bonding
- May improve depressive symptoms
- Appetite suppression and metabolic effects
- Up to 11.3% body weight reduction at 24 weeks (Phase 2, 6 mg dose)
- Significant reduction in liver fat content (NAFLD/MASH potential)
- Improves HbA1c and fasting glucose in type 2 diabetes
- Favorable lipid profile changes (reduced triglycerides)
- Once-weekly subcutaneous dosing
- Potential for superior weight loss vs GLP-1 monotherapy
- Side Effects
- Mild uterine cramping (avoid in pregnancy)
- Nasal irritation (intranasal)
- Headache
- Potential emotional over-attachment or jealousy amplification
- +2 more
- Nausea
- Vomiting
- Decreased appetite
- Diarrhea
- +3 more
- Stacks With
- —
- —